The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in ...
Business has been good for the company, which employs about 2,000 people and operates plants in Alabama and overseas. A few ...
For years, pharmacy benefit managers have been the target of ire for politicians ... it wanted that report retracted and was ...
In 2025, everyone enrolled in Part D will have their annual out-of-pocket drug costs capped at $2,000. In future years, that cap will rise in step with the rate of change in Part D costs.
The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...
The Federal Trade Commission said on Friday that it had taken legal action against the three largest pharmacy benefit ...
The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.
The Federal Trade Commission Friday announced it was suing the country's three biggest pharmacy benefit managers, claiming ...
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...
The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made ...
KARK Little Rock on MSN1d
Lawmakers approve several crucial funding measures for state agencies, Sanders’ security detail, PBM finesArkansas Legislative Council members signed off on several measures Friday in a committee meeting - impacting state prisons, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback